Innovita Clinic has been opened
Innovita Research has been issued a patent for its technology: Xenogenic normal tissue-derived vaccines for breaking the immune tolerance to tumor-associated, antigens. Seledtsov V.I., Darinskas A., Seledtsova G.V. Patent WO 2016046651 A1, 2016.
Permission to perform preclinical trial with novel xenogenic vaccines in mouse tumor model systems in vivo has been issued to Innovita Research team (permission number G2-22, issued at 2015-01-23 by Lithuanian Republic State Food and Veterinary Service).